Ozempic, Wegovy and other new drugs are selected for Medicare’s price negotiations
Biden administration says popular weight loss drugs have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers
Medicare to Negotiate Lower Prices for Weight-Loss Drugs
The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.
Explainer: What Wegovy's inclusion in Medicare price negotiation means for patients, company
The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027, which includes Novo Nordisk's blockbuster weight-loss drug Wegovy. Here's
Medicare to negotiate price of Ozempic, Wegovy weight-loss drugs
The Biden administration moved Friday to negotiate the prices Medicare pays for the blockbuster weight-loss drugs Ozempic and Wegovy, medications costing the massive government health program billions of dollars a year.
White House says popular weight-loss drug Ozempic subject to Medicare talks
The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a round of price negotiations with Medicare. The companies do not have to negotiate, but if they don’t, they face fines or the possible end of Medicare reimbursements.
Medicare announces 15 new drugs up for price negotiations, including Ozempic
The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, which includes Ozempic.
Biden administration selects 15 new medications up for price negotiations including weight loss drugs Ozempic and Wegovy
Biden administration selects 15 new medications up for price negotiations including weight loss drugs Ozempic and Wegovy.
Medicare's next round of drug negotiations
The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare negotiation. The CMS listed Ozempic, Rybelsus and Wegovy — all forms of semaglutide — at the top of the list of drugs for which Medicare will the negotiate the price of in 2025.
Biden administration adds 15 drugs to Medicare price negotiation list
Medicare enrollees, however, still won’t be able to access the drugs for obesity under a federal law that prohibits the program from paying for weight loss treatments. Right now
15 New Drugs Selected for Medicare Price Negotiations
The bad news is people on Medicare will have to wait a while before they see the savings. Retirees could feel the economic impact of President-elect Donald Trump prepares to reclaim office in Washington,
BioSpace6h
Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss in Phase III Trial
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
FiercePharma9h
Novo Nordisk touts 'superior' weight loss results in study of high-dose Wegovy
In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...
Websites selling compounded weight-loss drugs fail to inform patients of risks, research shows
Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...
Ozempic, Wegovy among drugs selected for Medicare's price negotiations
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...
Ozempic, Wegovy are among 15 drugs selected for Medicare’s price negotiations
U.S. Health and Human Services Secretary Xavier Becerra says “this is a big deal.” Drug companies oppose the program.
Zealand Seeks to Usurp Wegovy, Zepbound With New Obesity Drug
There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, ...
'I feel blessed to get weight-loss jab' - but can the NHS afford it for all?
We meet some of the first NHS patients, as expert says funding everyone eligible would "bankrupt" the service.
Gov. Hochul wants to lower cost of anti-obesity drugs, expand access to Medicaid recipients
The governor also said she would work with other states to leverage their combined purchasing power to reduce the cost of the ...